Oral low-dose etoposide therapy for refractory multiple myeloma with extramedullary involvement.
A 65-year-old man was hospitalized with IgG kappa-type multiple myeloma (MM) and enormous subcutaneous plasmacytomas. Two different combination chemotherapy regimens (MMCP and AVPP) and alpha-interferon therapy were ineffectual. Oral administration of etoposide at 50 mg/day was subsequently started, the tumors completely disappeared after 5 months. The blood level of monoclonal protein became undetectable after 8 months of continuous treatment. The side effect noted was loss of hair. The course in this patient suggests that long-term daily low-dose administration of etoposide should be attempted in patients with refractory MM and extramedullary plasmacytoma.
Kato
Y
Y
Second Department of Internal Medicine, Aichi Medical College.
Takeda
H
H
Mihara
H
H
Kobayashi
H
H
Kamijima
S
S
Kuwahara
M
M
Oguri
T
T
Nagasaka
T
T
D000284:Administration, Oral; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012074:Remission Induction
D011344:Procarbazine; D005047:Etoposide; D004317:Doxorubicin; D011239:Prednisolone